{"id":28235,"date":"2012-04-11T15:33:49","date_gmt":"2012-04-11T19:33:49","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/?post_type=news&#038;p=28235"},"modified":"2012-04-11T15:33:49","modified_gmt":"2012-04-11T19:33:49","slug":"study-evaluates-losartan-efficacy-in-heart-failure","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2012\/04\/11\/study-evaluates-losartan-efficacy-in-heart-failure\/","title":{"rendered":"Study Evaluates Losartan Efficacy in Heart Failure"},"content":{"rendered":"<p>The angiotensin II-receptor blocker (ARB) losartan has labored under the perception that it is not as potent as other ARBs, and some evidence has suggested that it may not confer the same clinical benefits as other ARBs in heart failure patients. In\u00a0<a href=\"http:\/\/jama.ama-assn.org\/content\/307\/14\/1506.short\">a paper from Denmark published in\u00a0<em>JAMA<\/em><\/a>,\u00a0Henrik Svanstr\u00f6m and colleagues performed a country-wide registry study in which they compared heart failure patients who were new users of losartan and candesartan.<\/p>\n<p>Overall there were no significant differences in mortality between the two groups:<\/p>\n<ul>\n<li>Adjusted hazard ratio (HR) for losartan:\u00a01.10, CI 0.96-1.25<\/li>\n<\/ul>\n<div>When compared with high-dose candesartan (16-32 mg), however, low-dose (12.5 mg) and medium-dose \u00a0(50 mg) losartan were linked to an increased risk for death, but this was not observed with high-dose (100 mg) losartan:<\/div>\n<div>\n<ul>\n<li>Low-dose losartan: HR 2.79, CI 2.19-3.55<\/li>\n<li>Medium-dose losartan: HR\u00a01.39, CI, 1.11-1.73<\/li>\n<li>High-dose losartan: HR 0.71, CI, 0.50-1.00<\/li>\n<\/ul>\n<\/div>\n<div>The authors concluded that their &#8220;findings do not support the hypothesis of differential effects of specific ARBs in patients with heart failure.&#8221;<\/div>\n","protected":false},"excerpt":{"rendered":"<p>The angiotensin II-receptor blocker (ARB) losartan has labored under the perception that it is not as potent as other ARBs, and some evidence has suggested that it may not confer the same clinical benefits as other ARBs in heart failure patients. In\u00a0a paper from Denmark published in\u00a0JAMA,\u00a0Henrik Svanstr\u00f6m and colleagues performed a country-wide registry study [&hellip;]<\/p>\n","protected":false},"author":196,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[14],"tags":[865,647,648,649],"class_list":["post-28235","post","type-post","status-publish","format-standard","hentry","category-heart-failure","tag-angiotensin-receptor-blockers","tag-arbs","tag-candesartan","tag-losartan"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/28235","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/196"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=28235"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/28235\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=28235"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=28235"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=28235"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}